CY1122684T1 - Εμβολιο ζωντανου εξασθενημενου χιμαιρικου χοιρειου κυκλοϊου - Google Patents

Εμβολιο ζωντανου εξασθενημενου χιμαιρικου χοιρειου κυκλοϊου

Info

Publication number
CY1122684T1
CY1122684T1 CY20201100165T CY201100165T CY1122684T1 CY 1122684 T1 CY1122684 T1 CY 1122684T1 CY 20201100165 T CY20201100165 T CY 20201100165T CY 201100165 T CY201100165 T CY 201100165T CY 1122684 T1 CY1122684 T1 CY 1122684T1
Authority
CY
Cyprus
Prior art keywords
vaccine
pcv2b
live attenuated
subtype
attenuated chimeric
Prior art date
Application number
CY20201100165T
Other languages
English (en)
Inventor
Xiang-Jin Meng
Nathan Beach
Sheela Ramamoorthy
Original Assignee
Virginia Tech Intellectual Properties, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties, Inc. filed Critical Virginia Tech Intellectual Properties, Inc.
Publication of CY1122684T1 publication Critical patent/CY1122684T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει νέο χιμαιρικό χοίρειου κυκλοϊού μολυσματώδη DΝΑ κλώνο και ζωντανό εξασθενημένο χιμαιρικό ιό με το ΡCV2, κατά προτίμηση υπότυπου ΡCV2b, γονίδιο καψιδίου ολοκληρωμένου εντός γονιδιώματος μη- παθογόνου PCV1 ιού. Σε μια ιδιαίτερη πραγματοποίηση, το γονίδιο καψιδίων ΡCV2 είναι υπότυπου ΡCV2b, ο κυρίαρχος υπότυπος που κυκλοφορεί σε χοίρους παγκοσμίως. Ο εξασθενημένος χιμαιρικός ιός, που ορίζεται ΡCVI-2b, προστατεύει αποτελεσματικά χοίρους από προκλήσεις ΡCV2b και μπορεί να χρησιμοποιηθεί ως ζωντανό εμβόλιο, καθώς επίσης ως απενεργοποιημένο (θανατωμένο) εμβόλιο, που παρέχει προστασία και εγκάρσια προστασία έναντι ΡCV2b και ΡCV2a υπότυπων μόλυνσης. Το ζωντανό εξασθενημένο εμβόλιο της παρούσας εφεύρεσης είναι επίσης αποτελεσματικό στην προστασία χοίρων από σχετική με χοίρειο κυκλοϊό ασθένεια (PCVAD).
CY20201100165T 2010-03-16 2020-02-21 Εμβολιο ζωντανου εξασθενημενου χιμαιρικου χοιρειου κυκλοϊου CY1122684T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31436210P 2010-03-16 2010-03-16
PCT/US2011/028665 WO2011116094A2 (en) 2010-03-16 2011-03-16 Live attenuated chimeric porcine circovirus vaccine

Publications (1)

Publication Number Publication Date
CY1122684T1 true CY1122684T1 (el) 2021-03-12

Family

ID=44649805

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100165T CY1122684T1 (el) 2010-03-16 2020-02-21 Εμβολιο ζωντανου εξασθενημενου χιμαιρικου χοιρειου κυκλοϊου

Country Status (15)

Country Link
US (3) US9585951B2 (el)
EP (2) EP2547770B1 (el)
CN (2) CN107261131A (el)
BR (1) BR112012023234A2 (el)
CY (1) CY1122684T1 (el)
DK (1) DK2547770T3 (el)
ES (1) ES2773722T3 (el)
HR (1) HRP20200258T1 (el)
HU (1) HUE047972T2 (el)
LT (1) LT2547770T (el)
PL (1) PL2547770T3 (el)
PT (1) PT2547770T (el)
RS (1) RS59952B1 (el)
SI (1) SI2547770T1 (el)
WO (1) WO2011116094A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EP2371382B1 (en) 2005-12-29 2016-03-02 Boehringer Ingelheim Vetmedica, Inc. Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
KR101619730B1 (ko) 2006-12-15 2016-05-12 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 항원을 이용한 돼지의 치료
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
HUE047972T2 (hu) * 2010-03-16 2020-05-28 Virginia Tech Intellectual Properties Inc Gyengített, élõ kiméra sertés cirkovírus vakcina
EP3035958B1 (en) 2013-08-23 2022-10-26 Boehringer Ingelheim Animal Health USA Inc. Porcine circovirus type 2 (pcv2) subunit vaccine
RU2662685C2 (ru) * 2013-09-25 2018-07-26 Зоэтис Сервисиз Ллс Pcv2b дивергентная вакцинная композиция и способы её применения
MX2016004063A (es) 2013-10-02 2016-06-06 Boehringer Ingelheim Vetmed Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
EP3277315A2 (en) * 2015-03-30 2018-02-07 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 carrier platform
CN104984335A (zh) * 2015-07-14 2015-10-21 浙江诺倍威生物技术有限公司 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备
JP7088835B2 (ja) * 2015-10-16 2022-06-21 カンザス ステイト ユニバーシティ リサーチ ファウンデーション ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
JP2019507784A (ja) * 2016-03-07 2019-03-22 ヴァージニア テック インテレクチュアル プロパティーズ，インコーポレーテッド キメラブタサーコウイルス２型（ｐｃｖ２）ワクチン
CN111892659A (zh) * 2020-07-20 2020-11-06 武汉科前生物股份有限公司 一种嵌合型猪圆环病毒PCV1-2d疫苗及其制备方法和应用
CN114908065B (zh) * 2022-05-07 2023-10-31 中国农业大学 猪伪狂犬病病毒基因工程弱毒疫苗株及其建立方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1693455A (zh) * 2005-04-08 2005-11-09 扬州大学 嵌合型猪圆环病毒pcv1－2及其构建方法、用途
TW200643171A (en) * 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
KR20100094587A (ko) 2007-12-21 2010-08-26 와이어쓰 엘엘씨 돼지 써코바이러스에 대해 돼지를 면역시키는 방법 및 조성물
HUE047972T2 (hu) * 2010-03-16 2020-05-28 Virginia Tech Intellectual Properties Inc Gyengített, élõ kiméra sertés cirkovírus vakcina

Also Published As

Publication number Publication date
PT2547770T (pt) 2020-03-04
BR112012023234A2 (pt) 2016-05-17
PL2547770T3 (pl) 2020-06-29
LT2547770T (lt) 2020-05-11
US9855327B2 (en) 2018-01-02
WO2011116094A2 (en) 2011-09-22
CN102971425A (zh) 2013-03-13
US9585951B2 (en) 2017-03-07
CN107261131A (zh) 2017-10-20
WO2011116094A3 (en) 2012-04-19
US20170173143A1 (en) 2017-06-22
EP2547770B1 (en) 2019-11-27
RS59952B1 (sr) 2020-03-31
SI2547770T1 (sl) 2020-07-31
HUE047972T2 (hu) 2020-05-28
US20110280905A1 (en) 2011-11-17
ES2773722T3 (es) 2020-07-14
EP3639852A1 (en) 2020-04-22
EP2547770A4 (en) 2013-10-16
US20140220067A1 (en) 2014-08-07
US9610344B2 (en) 2017-04-04
EP2547770A2 (en) 2013-01-23
HRP20200258T1 (hr) 2020-09-04
DK2547770T3 (da) 2020-03-02

Similar Documents

Publication Publication Date Title
CY1122684T1 (el) Εμβολιο ζωντανου εξασθενημενου χιμαιρικου χοιρειου κυκλοϊου
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
PH12018501602A1 (en) Subunit immersion vaccines for fish
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
GB2592769B (en) CpG-Adjuvanted SARS-CoV-2 virus vaccine
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
BR112018012642A2 (pt) vacina de calicivírus felino
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
EA201390812A1 (ru) Лиофилизированные вирусные составы
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
CO2017005830A2 (es) Composiciones de vacuna para el virus del dengue
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
MX339731B (es) Vacunas contra la bronquitis infecciosa derivadas de cepas similares a qx-bi.
CO6670515A2 (es) Vectores de parapoxvirus
EA201291179A1 (ru) Органические пероксидные соединения для инактивации микроорганизмов
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
PH12014501688A1 (en) Influenza c virus and vaccine
WO2014008475A3 (en) Compositions and methods related to viral vaccines
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
ZA202209826B (en) Inactivated sars-cov-2 virus vaccine
AR108664A1 (es) Vacuna contra la bronquitis infecciosa